Biopsy on progression in patients with EGFR mutation-positive advanced non-small-cell lung cancer-a Canadian experience.

ABSTRACT:

Background

Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) are standard therapy for patients with advanced or metastatic non-small-cell lung cancer harbouring an EGFR mutation. Upon progression, 50%-60% develop a secondary T790M mutation. Recent trials demonstrated outcome improvement with osimertinib compared with standard platinum-based chemotherapy as second-line therapy for patients with secondary T790M mutation. To identify T790M, a biopsy of the tumour or, more recently, plasma is necessary. This retrospective study aimed to evaluate biopsy procedures and mutational analysis at 2 Canadian cancer centres.

Methods

In a retrospective review of patients who were approached to enrol in the aura2, aura3, or astris studies, demographics, eligi

SUBMITTER: Chu Q 

PROVIDER: S-EPMC7096193 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature